Synthetic lipopeptide adjuvants and Toll-like receptor 2 - Structure-activity relationships

Vaccine

Volumn 22, Issue 19, 2004, Pages 2494-2499

  Spohn, Renate ^a   Buwitt Beckmann, Ute ^c   Brock, Roland ^b   Jung, Günther ^b   Ulmer, Artur J ^c   Wiesmüller, Karl Heinz ^a  

^a EMC MICROCOLLECTIONS GMBH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c RESEARCH CENTER BORSTEL   (Germany)

Author keywords

Lipopeptides; Structure activity relationship; Toll like receptor 2

Indexed keywords

ADJUVANT; AMINO ACID DERIVATIVE; FATTY ACID DERIVATIVE; GLYCERYLCYSTEINE; IMMUNOMODULATING AGENT; INTERLEUKIN 8; LIPOPEPTIDE; LIPOPROTEIN; PEPTIDE DERIVATIVE; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG;

ADAPTATION; CELLULAR IMMUNITY; CONFERENCE PAPER; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; EMBRYO; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFECTION; INFECTION PREVENTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ADJUVANTS, IMMUNOLOGIC; CELL LINE; HUMANS; LIPOPROTEINS; MEMBRANE GLYCOPROTEINS; PEPTIDES; RECEPTORS, CELL SURFACE; STRUCTURE-ACTIVITY RELATIONSHIP; TOLL-LIKE RECEPTOR 1; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTORS;

EID: 2942590448     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.11.074     Document Type: Conference Paper

References (42)

1. Gomes-Miguel M.J., Moriyon I., Alonso-Urmeneta B., Riezu-Boj J.I., Diaz R. Serological response to the outer membrane lipoprotein in animal brucellosis. Infekt. Immun. 56:1988;716-718
2. Herrmann A., Schlösser R., Schmid R., Schneider E. Biochemical identification of a lipoprotein with maltose-binding activity in the thermoacidophilic Gram-positive bacterium Alicyclobacillus acidocaldarius. Res. Microbiol. 147:1996;733-737
3. Weyer K.A., Schäfer W., Lottspeich F., Michel H. The cytochrome subunit of the photosynthetic reaction center from Rhodopseudomonas viridis is a lipoprotein. Biochemistry. 26:1987;2909-2914
4. Mühlrath P.F., Kieß M., Meyer H., Süßmuth R., Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J. Exp. Med. 185:1997;1951-1958
5. Braun V., Rehn K. Chemical characterization, spatial distribution and function of a lipoprotein (murein-lipoprotein) of the E. coli cell wall: the specific effect of trypsin on the membrane structure. Eur. J. Biochem. 10(3):1969;425-438
6. Hantke K., Braun V. Covalent binding of lipid to protein, diglyceride and amide-linked fatty acid at the N-terminal end of the murein-lipoprotein of the Escherichia coli outer membrane. Eur. J. Biochem. 34(2):1973;284-296
7. Braun V. Covalent lipoprotein from the outer membrane of Escherichia coli. Biochim. Biophys. Acta. 415:1975;335-377
8. Melchers F., Braun V., Galanos C. The lipoprotein of the outer membrane of Escherichia coli: a B-lymphocyte mitogen. J. Exp. Med. 142:1975;473-482
9. Norgard M.V., Arndt L.L., Akins D.R., Curetty L.L., Harrich D.A., Radolf J.D. Activation of human monocytic cells by Treponema pallidum and Borrelia burgdorferi lipoproteins and synthetic lipopeptides proceeds via a pathway distinct from that of lipopolysaccharide but involves the transcriptional activator NF-kappa B. Infect. Immun. 64(9):1996;3845-3852
10. Kreutz M., Ackermann U., Hauschildt S., Krause S.W., Riedel D., Bessler W., Andreesen R. A comparative analysis of cytokine production and tolerance induction by bacterial lipopeptides, lipopolysaccharides and Staphyloccous aureus in human monocytes. Immunology. 92(3):1997;396-401
11. Wiesmüller K.-H., Bessler W.G., Jung G. Synthesis of the mitogenic S-[2, 3-bis(palmitoyloxy)propyl]-N-palmitoylpentapeptide from Escherichia coli lipoprotein. Hoppe Seylers Z Physiol Chem. 364:1983;593-606
12. Bessler W.G., Cox M., Lex A., Suhr B., Wiesmüller K.-H., Jung G. Synthetic lipopeptide analogs of bacterial lipoprotein are potent polyclonal activators for murine B lymphocytes. J. Immunol. 135:1988;1900-1905
13. Hoffmann P., Heinle S., Schade U.F., Lopponow H., Ulmer A.J., Flad H.D., et al. Stimulation of human and murine adherent cells by bacterial lipoprotein and synthetic lipopeptide analogues. Immunobiology. 177(2):1988;158-170
14. 4. Involvement of guanine-nucleotide-binding proteins and synergism with chemotactic peptides. Biochem. J. 267(3):1990;795-802
15. 4 is an effective activator of human platelets. Am. J. Physiol. 266:1994;C1684-C1691
16. Wiesmüller K.-H., Bessler W.G., Jung G. Solid phase peptide synthesis of lipopeptide vaccines eliciting epitope-specific B-, T-helper and T-killer cell response. Int. J. Pept. Protein Res. 40:1992;255-260
17. Wiesmüller K.-H., Jung G., Hess G. Novel low-molecular-weight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator. Vaccine. 7:1989;29-33
18. Höhlich B-J, Wiesmüller K-H, Haas B, Gerner W., Correa R., Hehnen H.-R., et al. Induction of an antigen-specific immune response and partial protection of cattle against challenge infection with foot-and-mouth disease virus (FMDV) after lipopeptide vaccination with FMDV-specific B-cell epitopes. J Gen Virol, 2003;84:3315-24.
19. Deres K., Schild H.-J., Wiesmüller K.-H., Jung G., Rammensee H.-G. In vivo priming of virus specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature. 342:1989;561-564
20. h)-cell epitope. FEMS Immunol. Med. Microb. 17:1997;225-234
21. Moran E., O'Keeffe M., O'Connor R., Larkin A.M., Murphy P., Clynes M. Methods for generation of monoclonal antibodies to the very small drug hapten, 5-benzimidazole-carboxylic acid. J. Immunol. Methods. 271(1-2):2002;65-75
22. Wiedemann F., Link R., Pumpe K., Jakobshagen U., Schäfer H.E., Wiesmüller K.-H., et al. Histopathological studies on the local reactions induced by complete Freund's adjuvant (FCA), bacterial lipopolysaccharide (LPS) and synthetic lipopeptide (P3C) conjugates. J. Pathology. 164:1990;1-7
23. Seth A., Yasutomi Y., Jacoby H., Callery J.C., Kaminsky S.M., Koff W.C., et al. Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals. AIDS Res. Hum. Retroviruses. 16(4):2000;337-343
24. Keller D., Koster F.T., Marks D.H., Hosbach P., Erdile L.F., Mays J.P. Safety and immunogenicity of a recombinant outer surface protein Lyme vaccine. J. Am. Med. Assoc. 271:1994;1764-1768
25. Hioe C.E., Qiu H., Chend P.D., Bian Z., Li M.L., Li J., et al. Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides. Vaccine. 5:1996;412-418
26. Aliprantis A.O., Yang R.B., Mark M.R., Suggett S., Devaux B., Radolf J.D., et al. Cell activation and apoptosis by bacterial lipoproteins through Toll-like receptor-2. Science. 285:1999;736-739
27. Means T.K., Golenbock D.T., Fenton M.J. The biology of Toll-like receptors. Cytokine Growth Factor Rev. 11:2000;219-232
28. Janeway C.A. Jr., Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20:2002;197-216
29. Akira S. Mammalian Toll-like receptors. Curr. Opin. Immunol. 15:2003;5-11
30. Tsunoda I., Sette A., Fujinami R.S., Oseroff C., Ruppert J., Dahlberg C., et al. Lipopeptide particles as the immunologically active component of CTL inducing vaccines. Vaccine. 17:1999;675-685
31. Schnare M., Barton G.M., Holt A.C., Takeda K., Akira S., Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2:2001;947-950
32. Sieling P.A., Chung W., Duong B.T., Godowski P.J., Modlin R.L. Toll-like receptor 2 ligands as adjuvants for human Th1 responses. J. Immunol. 170:2003;194-200
33. Heine H., Lien E. Toll-like receptors and their function in innate and adaptive immunity. Int. Arch. Allergy Immunol. 130:2003;180-192
34. Ozinsky A., Underhill D.M., Fontenot J.D., Hajjar A.M., Smith K.D., Wilson C.B., et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc. Natl. Acad. Sci. U.S.A. 97:2000;13766-13771
35. Alexopoulou L., Thomas V., Schnare M., Lobet Y., Anguita J., Schoen R.T., et al. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat. Med. 8:2002;878-884
36. Morr M., Takeuchi O., Akira S., Simon M.M., Mühlradt P.F. Differential recognition of structural details of bacterial lipopeptides by Toll-like receptors. Eur. J. Immunol. 32:2002;3337-3347
37. Takeuchi O., Kawai T., Mühlradt P.F., Morr M., Radolf J.D., Zychlinsky A., et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int. Immunol. 13:2001;933-940
38. Takeuchi O., Sato S., Horiuchi T., Hoshino K., Takeda K., Dong Z., et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. 169:2002;10-14
39. Takeuchi O., Kaufmann A., Grote K., et al. Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a Toll-like receptor 2- and MyD88-dependent signaling pathway. J. Immunol. 164(2):2000;554-557
40. Metzger J.W., Kempter C., Wiesmüller K.-H., Jung G. Electrospray mass spectrometry and tandem mass spectrometry of synthetic multicomponent peptide mixtures: determination of composition and purity. Anal. Biochem. 219(2):1994;261-277
41. Kienle S., Wiesmüller K.-H., Brünjes J., Metzger J.W., Jung G. MS-Pep: A computer program for the interpretation of mass spectra of peptide libraries. Fresenius J. Anal. Chem. 359:1997;10-14
42. Reitermann A., Metzer J., Wiesmüller K.-H., Jung G., Bessler W.G. Lipopeptide derivatives of bacterial lipoprotein constitute potent immune adjuvants combined with or covalently coupled to antigen or hapten. Biol. Chem. Hoppe-Seyler. 370:1989;343-352